Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 1 Μαρ 2022 · EDTA is an intravenous chelating agent with high affinity to divalent cations (lead, cadmium, and calcium) that may be beneficial in the treatment of cardiovascular disease (CVD). Although a large randomized clinical trial showed benefit, smaller studies were inconsistent.

  2. The National Institutes of Health (NIH) has sponsored two trials of an EDTA (edetate) chelation therapy regimen for coronary heart disease (CHD). The first study, called the Trial to Assess Chelation Therapy (TACT), has been completed.

  3. Two of the earliest randomized controlled trials, by Kitchell et al., 1963 and Olszewer et al., 1990 , found EDTA chelation therapy to have a beneficial effect on cardiovascular risk profiles when compared to control. In the first trial by Kitchell et al., 50% of the active group experienced improved ECG readings after 6 and 12 weeks following ...

  4. 1 Ιουλ 2014 · The National Institutes of Healthfunded Trial to Assess Chelation Therapy (TACT) randomized 1708 stable coronary disease patients aged ≥50 years who were ≥6 months post–myocardial infarction (2003–2010) to 40 infusions of a multicomponent EDTA chelation solution or placebo.

  5. 1 Μαρ 2022 · Twenty‐four studies (4 randomized clinical trials, 15 prospective before/after studies, and 5 retrospective case series) assessed the use of repeated EDTA chelation treatment in patients with preexistent CVD.

  6. Importance In 2013, the Trial to Assess Chelation Therapy (TACT) reported that edetate disodium (EDTA)–based chelation significantly reduced cardiovascular disease (CVD) events by 18% in 1708 patients with a prior myocardial infarction (MI).

  7. TACT2 may provide definitive evidence of the benefit of edetate disodiumbased chelation on cardiovascular outcomes, as well as the clinical importance of longitudinal changes in toxic metal levels of participants.

  1. Γίνεται επίσης αναζήτηση για